Amani Therapeutics Raises $25M Series A to Unlock Safer Use of Clozapine for Schizophrenia

Amani Therapeutics just stepped onto the floor with $25M in Series A funding, and this one carries a different kind of weight. Not loud money. Intentional money. Backed by RTW Investments, the kind of capital that doesn’t blink at complexity, only at conviction. New York built, biotech at its core, and aimed straight at one of medicine’s most stubborn paradoxes.

Clozapine works. That’s the quiet truth everyone in neuropsychiatry already knows. It hits where others miss, especially in treatment resistant schizophrenia. But it comes with a shadow. Severe neutropenia, constant blood monitoring, friction at every step. So what happens? The best tool in the drawer stays there. Effective, but underused. That’s not a science problem. That’s an execution problem.

Amani Therapeutics is leaning into that tension with AM-01, a fixed dose combination pairing clozapine with a Phase 3 ready novel chemical entity licensed from AstraZeneca. Not starting from scratch. Not guessing. Walking in with data, rights, and a clear thesis. Reduce the risk, ease the burden, keep the efficacy. If they pull that off, you’re not just improving a drug. You’re unlocking one that’s been sitting on the bench for too long.

Credit where it’s due. Rob Swoboda stepping in as COO brings a track record shaped at Karuna Therapeutics, bluebird bio, and Vertex Pharmaceuticals. Carla Canuso, MD, as CMO, carries more than 20+ years of neuropsychiatric development experience, including leadership at Johnson & Johnson and work on intranasal esketamine. This is not a team learning the language. They’ve been writing in it for years. Tricia Cotter, Praveen Kandi, Alexander Vandell, Jaclyn Scott, and Jessica Gagne round out a group built for the long, clinical grind.

And let’s not ignore the business lesson hiding in plain sight. Amani Therapeutics didn’t chase novelty for the sake of headlines. They found a high efficacy asset with a known ceiling, then engineered a path to raise that ceiling by solving the constraint. Add in a strategic in license from AstraZeneca and a focused capital partner in RTW Investments, and suddenly “newly formed” doesn’t mean early. It means precise.

This is what smart biotech looks like when it respects both the molecule and the market. Not louder. Just sharper. And in a space where patients have been waiting far too long, sharp tends to win.